Literature DB >> 33983601

Minimal Invasive and Individualizing Management of the Axillary Nodes.

Jun Won Min1, Jihyoung Cho2.   

Abstract

The status of the axillary lymph nodes is one of the most important prognostic factors for patients with breast cancer. For over 100 years, axillary lymph node dissection was the standard approach to obtain and manage axillar lymph node, but now, sentinel lymph node biopsy has become a standard approach with less morbidity and equal accuracy in clinical node-negative patients. In addition, numerous studies are on the way to omit axillary lymph node dissection in specific patient subgroups. The recent trials like the ACOSOG Z0011 showed the evidence that omitting an ALND in patients with low burden nodal disease is safe in patients receiving whole-breast radiation. To reduce the use of ALND is the goal to consider when selecting an axillary management strategy.

Entities:  

Keywords:  Axillary lymph node; Axillary lymph node dissection; Breast cancer; Neoadjuvant chemotherapy; Sentinel lymph node biopsy

Mesh:

Year:  2021        PMID: 33983601     DOI: 10.1007/978-981-32-9620-6_31

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  35 in total

Review 1.  Sentinel lymph node biopsy in breast cancer: a history and current clinical recommendations.

Authors:  Desiree D D'Angelo-Donovan; Diana Dickson-Witmer; Nicholas J Petrelli
Journal:  Surg Oncol       Date:  2012-01-10       Impact factor: 3.279

Review 2.  Value of preoperative ultrasound-guided axillary lymph node biopsy for preventing completion axillary lymph node dissection in breast cancer: a systematic review and meta-analysis.

Authors:  Suzanne C E Diepstraten; Ali R Sever; Constantinus F M Buckens; Wouter B Veldhuis; Thijs van Dalen; Maurice A A J van den Bosch; Willem P Th M Mali; Helena M Verkooijen
Journal:  Ann Surg Oncol       Date:  2013-09-06       Impact factor: 5.344

3.  Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe.

Authors:  D N Krag; D L Weaver; J C Alex; J T Fairbank
Journal:  Surg Oncol       Date:  1993-12       Impact factor: 3.279

4.  Is Preoperative Axillary Imaging Beneficial in Identifying Clinically Node-Negative Patients Requiring Axillary Lymph Node Dissection?

Authors:  Melissa Pilewskie; Maxine Jochelson; Jessica C Gooch; Sujata Patil; Michelle Stempel; Monica Morrow
Journal:  J Am Coll Surg       Date:  2015-11-25       Impact factor: 6.113

5.  Learning sentinel node biopsy: results of a prospective randomized trial of two techniques.

Authors:  M Morrow; A W Rademaker; K P Bethke; M S Talamonti; L G Dawes; J Clauson; N Hansen
Journal:  Surgery       Date:  1999-10       Impact factor: 3.982

6.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.

Authors:  Robert E Mansel; Lesley Fallowfield; Mark Kissin; Amit Goyal; Robert G Newcombe; J Michael Dixon; Constantinos Yiangou; Kieran Horgan; Nigel Bundred; Ian Monypenny; David England; Mark Sibbering; Tholkifl I Abdullah; Lester Barr; Utheshtra Chetty; Dudley H Sinnett; Anne Fleissig; Dayalan Clarke; Peter J Ell
Journal:  J Natl Cancer Inst       Date:  2006-05-03       Impact factor: 13.506

7.  Lymphatic drainage of skin to a sentinel lymph node in a feline model.

Authors:  J H Wong; L A Cagle; D L Morton
Journal:  Ann Surg       Date:  1991-11       Impact factor: 12.969

8.  Lymphatic mapping and sentinel lymphadenectomy for breast cancer.

Authors:  A E Giuliano; D M Kirgan; J M Guenther; D L Morton
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

Review 9.  Clinical utility of ultrasound-needle biopsy for preoperative staging of the axilla in invasive breast cancer.

Authors:  Nehmat Houssami; Suzanne C E Diepstraten; Hiram S Cody; Robin M Turner; Ali R Sever
Journal:  Anticancer Res       Date:  2014-03       Impact factor: 2.480

10.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer.

Authors:  Umberto Veronesi; Giovanni Paganelli; Giuseppe Viale; Alberto Luini; Stefano Zurrida; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Chris Robertson; Patrick Maisonneuve; Giuseppe Renne; Concetta De Cicco; Francesca De Lucia; Roberto Gennari
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.